Increasing symptoms in irritable bowel symptoms with ingestion of galacto-oligosaccharides are mitigated by α-galactosidase treatment

American Journal of Gastroenterology

Volumn 113, Issue 1, 2018, Pages 124-134

  Tuck, C J ^a   Taylor, K M ^a   Gibson, P R ^a   Barrett, J S ^a   Muir, J G ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; GALACTOSE OLIGOSACCHARIDE; GALACTOSE; OLIGOSACCHARIDE;

ADULT; ARTICLE; BLOATING; BREATH ANALYSIS; CARBOHYDRATE DIET; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY INTAKE; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROGEN BREATH TEST; IRRITABLE COLON; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VISUAL ANALOG SCALE; CHEMICALLY INDUCED; DISEASE EXACERBATION; MIDDLE AGED; PATHOPHYSIOLOGY; YOUNG ADULT;

ADULT; ALPHA-GALACTOSIDASE; BREATH TESTS; CROSS-OVER STUDIES; DIETARY CARBOHYDRATES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GALACTOSE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; OLIGOSACCHARIDES; YOUNG ADULT;

EID: 85048094815     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2017.245     Document Type: Article

References (51)

1. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. American college of gastroenterology task force on irritable bowel syndrome. Am J Gastroenterol 2009; 104: S1-35.
2. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015; 313: 949-58.
3. Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75
4. Lacy BE, Mearin F, Chang L et al. Bowel disorders. Gastroenterology 2016; 150: 1393-407.
5. Gibson PR, Shepherd SJ. Personal view: food for thought-western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005; 21: 1399-409.
6. Barrett JS, Gearry RB, Muir JG et al. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 2010; 31: 874-82.
7. Murray K, Wilkinson-Smith V, Hoad C et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 2013; 109: 110-9.
8. Ong DK, Mitchell SB, Barrett JS et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1366-73.
9. Staudacher HM, Lomer MCE, Anderson JL et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012; 142: 1510-8.
10. De Roest RH, Dobbs BR, Chapman BA et al. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: A prospective study. Int J Clin Pract 2013; 67: 895-903.
11. Bohn L, Storsrud S, Liljebo T et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 2015; 149: 1399-407.
12. Eswaran SL, Chey WD, Han-Markey T et al. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol 2016; 111: 1824-32.
13. Portincasa P, Di Ciaula A, Vacca M et al. Beneficial effects of oral tilactase on patients with hypolactasia. Eur J Clin Invest 2008; 38: 835-44.
14. Lin MY, Dipalma JA, Martini MC et al. Comparative effects of exogenous lactase (β -galactosidase) preparations on in vivo lactose digestion. Dig Dis Sci 1993; 38: 2022-7.
15. Solomons NW, Guerrero AM, Zepada E et al. The efficacy of an oral alphagalactosidase to promote oligosaccharide hydrolysis and to reduce intolerance symptoms aft er ingestion of beans: a dose-response trial. Clin Res 1991; 39: 655A.
16. Ganiats TG, Norcross WA, Halverson AL et al. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. J Fam Practice 1994; 39: 441-5.
17. Di Stefano M, Miceli E, Gotti S et al. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci 2007; 52: 78-83.
18. Rupp TH, Wright RA. Does beano work. Gastroenterology 1993; 104: A276.
19. Solomons NW, Vettorazzi L, Grazioso C. Use of an oral alphagalactosidase to control gastrointestinal symptoms from legume oligosaccharides in bean-intolerant subjects: a doubly-masked, controlled, therapeutic trial. Clin Res 1991; 39: 428A.
20. Di Nardo G, Oliva S, Ferrari F et al. Efficacy and tolerability of α -galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. BMC gastroenterology 2013; 13: 1.
21. Hillila M, Farkkila MA, Sipponen T et al. Does oral α -galactosidase relieve irritable bowel symptoms? Scand J Gastroenterol 2016; 51: 16-21.
22. Di Pierro F, Bertuccioli A, Marini E et al. a pilot trial on subjects with lactose and/or oligosaccharides intolerance treated with a fixed mixture of pure and enteric-coated α -and β -galactosidase. Clin Exp Gastroenterol 2015; 8: 95.
23. Muir JG, Shepherd SJ, Rosella O et al. Fructan and free fructose content of common Australian vegetables and fruit. J Agric Food Chem 2007; 55: 6619.
24. Muir JG, Rose R, Rosella O et al. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC). J Agric Food Chem 2009; 57: 554.
25. Biesiekierski JR, Rosella O, Rose R et al. Quantification of fructans, galactooligosacharides and other short-chain carbohydrates in processed grains and cereals. J Hum Nutr Diet 2011; 24: 154-76.
26. Bengtsson M, Persson J, Sjolund K et al. Further validation of the visual analogue scale for irritable bowel syndrome aft er use in clinical practice. Gastroenterol Nurs 2013; 36: 188-98.
27. Tuck C, Ross L, Gibson P et al. Adding glucose to food and solutions to enhance fructose absorption is not effective in preventing fructose-induced functional gastrointestinal symptoms: randomised controlled trials in patients with fructose malabsorption. J Hum Nutr Diet 2017; 30: 73-82.
28. Chey WD. Food: the main course to wellness and illness in patients with irritable bowel syndrome. Am J Gastroenterol 2016; 111: 366-71.
29. Tuck CJ, Muir JG, Barrett JS et al. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2014; 8: 819-34.
30. Sikkens EC, Cahen DL, Kuipers EJ et al. Pancreatic enzyme replacement therapy in chronic pancreatitis. Best Pract Res Clin Gastroenterol 2010; 24: 337-47.
31. Trang T, Chan J, Graham DY. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st century. World J Gastroenterol 2014; 20: 11467.
32. Dominguez-Munoz J, Iglesias-Garcia J, Iglesias-Rey M et al. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three-way crossover study. Aliment Pharmacol Ther 2005; 21: 993-1000.
33. Dominguez-Munoz J. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency: when is it indicated, what is the goal and how to do it? Adv Med Sci 2011; 56: 1-5.
34. Barrett JS, Gibson PR. Development and validation of a comprehensive semi-quantitative food frequency questionnaire that includes FODMAP intake and glycemic index. J Am Diet Assoc 2010; 110: 1469-76.
35. Halmos EP, Christophersen CT, Bird AR et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015; 64: 93-100.
36. Gibson GR, Beatty ER, Wang X et al. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 1995; 108: 975-82.
37. Ito M, Deguchi Y, Miyamori A et al. Effects of administration of galactooligosaccharides on the human faecal microflora, stool weight and abdominal sensation. Microb Ecol Health Dis 1990; 3: 285-92.
38. Yao CK, Tuck CJ, Barrett JS et al. Poor reproducibility of breath hydrogen testing: Implications for its application in functional bowel disorders. United European Gastroenterol J 2017; 5: 284-92.
39. Kalantar-Zadeh K, Yao CK, Berean KJ et al. Intestinal gas capsules: A proof-of-concept demonstration. Gastroenterology 2016; 150: 37-9.
40. Davis L, Martinez I, Walter J et al. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol 2010; 144: 285-92.
41. Silk DB, Davis A, Vulevic J et al. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508-18.
42. Bouhnik Y, Flourie B, D'Agay-Abensour L et al. Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nutr 1997; 127: 444-8.
43. Riviere A, Selak M, Lantin D et al. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 2016; 7: 979.
44. Hernot DC, Boileau TW, Bauer LL et al. In vitro fermentation profiles, gas production rates, and microbiota modulation as affected by certain fructans, galactooligosaccharides, and polydextrose. J Agric Food Chem 2009; 57: 1354-61.
45. Vanhoutvin S, Troost F, Kilkens T et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21: 952 - e76.
46. Bourdu S, Dapoigny M, Chapuy E et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005; 128: 1996-2008.
47. McIntosh K, Reed DE, Schneider T et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut 2016; 66: 1241-51. gutjnl-2015.
48. Poslusna K, Ruprich J, de Vries JH et al. Misreporting of energy and micronutrient intake estimated by food records and 24 hour recalls, control and adjustment methods in practice. Br J Nutr 2009; 101: S73-85.
49. Yao CK, Gibson PR, Shepherd SJ. Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders. Am J Gastroenterol 2013; 108: 748-58.
50. Rebro SM, Patterson RE, Kristal AR et al. The effect of keeping food records on eating patterns. J Am Diet Assoc 1998; 98: 1163-5.
51. Tuck CJ, Barrett JS. Re-challenging FODMAPs: The low FODMAP diet phase two. J Gastroenterol Hepatol 2017; 32: 11-15.